Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 27:2022:4761631.
doi: 10.1155/2022/4761631. eCollection 2022.

Association of Interleukin-17F Polymorphism and Mortality Predictors with the Risk of COVID-19

Manal M El-Desoky  1 , Samar Tharwat  2 , Nora Mostafa  1 , Asem A Hewidy  3 , Rehab A Elmorsey  3 , Mona S Abdelhafez  4 , Amira H El-Ashry  4 , Mona M Elhendawi  5 , Aya Ahmed Fathy  6 , Fatma Azzahraa Hisham  1
Affiliations

Association of Interleukin-17F Polymorphism and Mortality Predictors with the Risk of COVID-19

Manal M El-Desoky et al. Int J Clin Pract. .

Abstract

Background: Th-17 cells, a proinflammatory subset of CD4 T lymphocytes, have been suggested as a possible cause of coronavirus disease-19 (COVID-19)-related immunological injuries. The aim of this study was to investigate the relationship between IL-17F (rs763780) polymorphism and the susceptibility to and outcomes of COVID-19 infection and to determine the clinical and laboratory predictors of COVID-19 death.

Methods: This case-control study included 132 COVID-19 patients and 135 healthy age- and sex-matched controls. The participants were tested for IL-17F rs763780 polymorphism via TaqMan-based genotyping and for the expression of IL-17 by enzyme-linked immunosorbent assay. This study also investigated the predictors for COVID-19 mortality.

Results: A non-statistically significant association was observed between IL-17F alleles and genotypes with COVID-19 (P=0.309, P=0.138, respectively). Moreover, no significant difference in the IL-17F genotypes was observed between non-survivors and survivors (P=0.482). In the multivariate analysis, the participants with the following characteristics had 17.7-, 11.2-, 8-, and 17.9-fold higher odds of exhibiting in-hospital mortality, respectively: (1) hypertension, (2) age of >57 years, (3) WBC count of >12.6 × 103/mm3, and (4) D-dimer of >0.9 ng/ml. The ROC curve analysis showed that IL-17 at a cutoff point of >46 pg/ml was a perfect discriminator of COVID-19 patients from control subjects (AUC = 1.0).

Conclusion: The findings indicate that the IL-17F H161R variant does not influence the risk of COVID-19. However, the IL-17 level is a perfect discriminator of COVID-19 infection. Hypertension, age of >57 years, white blood cell count of >12.6 × 103/mm3, and D-dimer of >0.9 ng/ml are the independent predictors for death among COVID-19 patients.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Serum level of IL-17 in the study COVID-19 patients (n = 132) and healthy controls (n = 135). P < 0.001.
Figure 2
Figure 2
A ROC curve analysis for IL-17 concentration as a discriminator of COVID-19 patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Vannabouathong C., Devji T., Ekhtiari S., et al. Novel coronavirus COVID-19: current evidence and evolving strategies. Journal of Bone and Joint Surgery . 2020;102(9):734–744. doi: 10.2106/jbjs.20.00396. - DOI - PMC - PubMed
    1. Öztürk R., Taşova Y., Ayaz A. COVID-19: pathogenesis, genetic polymorphism, clinical features and laboratory findings. Turkish Journal of Medical Sciences . 2020;50(3):638–657. doi: 10.3906/sag-2005-287. - DOI - PubMed
    1. Qin C., Zhou L., Hu Z., et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in wuhan, China. Clinical Infectious Diseases . 2020;71(15):762–768. doi: 10.1093/cid/ciaa248. - DOI - PMC - PubMed
    1. Kaabachi W., Amor A. b, Kaabachi S., Rafrafi A., Tizaoui K., Hamzaoui K. Interleukin-17A and -17F genes polymorphisms in lung cancer. Cytokine . 2014;66(1):23–29. doi: 10.1016/j.cyto.2013.12.012. - DOI - PubMed
    1. Kim S. Y., Hur M. S., Choi B. G., et al. A preliminary study of new single polymorphisms in the T helper type 17 pathway for psoriasis in the Korean population. Clinical and Experimental Immunology . 2017;187(2):251–258. doi: 10.1111/cei.12888. - DOI - PMC - PubMed